The role of radiotherapy in the treatment of localised intermediate and high grade non-Hodgkin's lymphoma in elderly patients

Background and purpose: The treatment of elderly patients with high or intermediate grade non-Hodgkin's lymphoma (NHL) remains difficult and controversial. In order to audit our own practice, 270 elderly patients treated between 1988 and 1993 with this diagnosis were retrospectively reviewed. M...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Radiotherapy and oncology 1998-10, Vol.49 (1), p.9-14
Hauptverfasser: Wylie, James P, Cowan, Richard A, Deakin, David P
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 14
container_issue 1
container_start_page 9
container_title Radiotherapy and oncology
container_volume 49
creator Wylie, James P
Cowan, Richard A
Deakin, David P
description Background and purpose: The treatment of elderly patients with high or intermediate grade non-Hodgkin's lymphoma (NHL) remains difficult and controversial. In order to audit our own practice, 270 elderly patients treated between 1988 and 1993 with this diagnosis were retrospectively reviewed. Material and methods: 81 patients unfit for chemotherapy received fractionated radiotherapy for apparently localised stage I or II disease. The median age of the patients was 78 years (range 70–87 years). Forty stage I and 17 stage II patients had extra-nodal sites of disease. The radiation field included the primary site plus immediate adjacent nodes. Results: After a median follow-up of 3.9 years the 5-year overall and disease-free survival rates were 33% and 31%, respectively. Age (hazard ratio (HR) 1.22, P=0.03), stage (HR 5.50, P=0.02) and lactate dehydrogenase level (HR 1.003, P=0.004) were identified as independent risk factors for relapse. Conclusion: These factors can define a group in which radiotherapy can produce acceptable survival rates (age≤80 years, stage I and lactate dehydrogenase≤500). This group represented 34% of those patients where all these variables were recorded and had 5-year disease-free and overall survival rates of 56% and 62%, respectively.
doi_str_mv 10.1016/S0167-8140(98)00068-1
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69133846</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0167814098000681</els_id><sourcerecordid>69133846</sourcerecordid><originalsourceid>FETCH-LOGICAL-c360t-711b6bcdece5d8c9993bb194afeb0c5b23ba9c5b14d4ec798e25ebb0bc1c48b93</originalsourceid><addsrcrecordid>eNqFkElPwzAQhS0EKmX5CUg-sRwCdpMm9gkhxCYhcaCcLS_TxuDEwXaReuC_49KKK5eZkd6bN5oPoRNKLimh9dVrLk3BaEXOObsghNSsoDtoTFnDC8JYs4vGf5Z9dBDjezZNSNmM0IgzVtecjtH3rAUcvAPs5zhIY31qIchhhW2P84hTAJk66NPa4LyWzkYwWU0QOjBWJsCyN7i1ixYvcgLg3vfFozeLD9ufRexW3dD6Tq4DwRkIboUHmWyOjEdoby5dhONtP0Rv93ez28fi-eXh6fbmudBlTVLRUKpqpQ1omBqmOeelUpRXcg6K6KmalEry3GllKtANZzCZglJEaaorpnh5iE43uUPwn0uISXQ2anBO9uCXUWQUZcmqOhunG6MOPsYAczEE28mwEpSINXbxi12smQrOxC92QfPeyfbAUmUqf1tbzlm_3uiQv_yyEETUmYDOAAPoJIy3_1z4AffYlVQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69133846</pqid></control><display><type>article</type><title>The role of radiotherapy in the treatment of localised intermediate and high grade non-Hodgkin's lymphoma in elderly patients</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Wylie, James P ; Cowan, Richard A ; Deakin, David P</creator><creatorcontrib>Wylie, James P ; Cowan, Richard A ; Deakin, David P</creatorcontrib><description>Background and purpose: The treatment of elderly patients with high or intermediate grade non-Hodgkin's lymphoma (NHL) remains difficult and controversial. In order to audit our own practice, 270 elderly patients treated between 1988 and 1993 with this diagnosis were retrospectively reviewed. Material and methods: 81 patients unfit for chemotherapy received fractionated radiotherapy for apparently localised stage I or II disease. The median age of the patients was 78 years (range 70–87 years). Forty stage I and 17 stage II patients had extra-nodal sites of disease. The radiation field included the primary site plus immediate adjacent nodes. Results: After a median follow-up of 3.9 years the 5-year overall and disease-free survival rates were 33% and 31%, respectively. Age (hazard ratio (HR) 1.22, P=0.03), stage (HR 5.50, P=0.02) and lactate dehydrogenase level (HR 1.003, P=0.004) were identified as independent risk factors for relapse. Conclusion: These factors can define a group in which radiotherapy can produce acceptable survival rates (age≤80 years, stage I and lactate dehydrogenase≤500). This group represented 34% of those patients where all these variables were recorded and had 5-year disease-free and overall survival rates of 56% and 62%, respectively.</description><identifier>ISSN: 0167-8140</identifier><identifier>EISSN: 1879-0887</identifier><identifier>DOI: 10.1016/S0167-8140(98)00068-1</identifier><identifier>PMID: 9886691</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Age Factors ; Aged ; Aged, 80 and over ; Disease-Free Survival ; Elderly ; Female ; High/intermediate grade ; Humans ; Lymphoma, Non-Hodgkin - mortality ; Lymphoma, Non-Hodgkin - radiotherapy ; Male ; Non-Hodgkin's lymphoma ; Radiotherapy ; Survival Rate</subject><ispartof>Radiotherapy and oncology, 1998-10, Vol.49 (1), p.9-14</ispartof><rights>1998 Elsevier Science Ireland Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c360t-711b6bcdece5d8c9993bb194afeb0c5b23ba9c5b14d4ec798e25ebb0bc1c48b93</citedby><cites>FETCH-LOGICAL-c360t-711b6bcdece5d8c9993bb194afeb0c5b23ba9c5b14d4ec798e25ebb0bc1c48b93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0167814098000681$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9886691$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wylie, James P</creatorcontrib><creatorcontrib>Cowan, Richard A</creatorcontrib><creatorcontrib>Deakin, David P</creatorcontrib><title>The role of radiotherapy in the treatment of localised intermediate and high grade non-Hodgkin's lymphoma in elderly patients</title><title>Radiotherapy and oncology</title><addtitle>Radiother Oncol</addtitle><description>Background and purpose: The treatment of elderly patients with high or intermediate grade non-Hodgkin's lymphoma (NHL) remains difficult and controversial. In order to audit our own practice, 270 elderly patients treated between 1988 and 1993 with this diagnosis were retrospectively reviewed. Material and methods: 81 patients unfit for chemotherapy received fractionated radiotherapy for apparently localised stage I or II disease. The median age of the patients was 78 years (range 70–87 years). Forty stage I and 17 stage II patients had extra-nodal sites of disease. The radiation field included the primary site plus immediate adjacent nodes. Results: After a median follow-up of 3.9 years the 5-year overall and disease-free survival rates were 33% and 31%, respectively. Age (hazard ratio (HR) 1.22, P=0.03), stage (HR 5.50, P=0.02) and lactate dehydrogenase level (HR 1.003, P=0.004) were identified as independent risk factors for relapse. Conclusion: These factors can define a group in which radiotherapy can produce acceptable survival rates (age≤80 years, stage I and lactate dehydrogenase≤500). This group represented 34% of those patients where all these variables were recorded and had 5-year disease-free and overall survival rates of 56% and 62%, respectively.</description><subject>Age Factors</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Disease-Free Survival</subject><subject>Elderly</subject><subject>Female</subject><subject>High/intermediate grade</subject><subject>Humans</subject><subject>Lymphoma, Non-Hodgkin - mortality</subject><subject>Lymphoma, Non-Hodgkin - radiotherapy</subject><subject>Male</subject><subject>Non-Hodgkin's lymphoma</subject><subject>Radiotherapy</subject><subject>Survival Rate</subject><issn>0167-8140</issn><issn>1879-0887</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkElPwzAQhS0EKmX5CUg-sRwCdpMm9gkhxCYhcaCcLS_TxuDEwXaReuC_49KKK5eZkd6bN5oPoRNKLimh9dVrLk3BaEXOObsghNSsoDtoTFnDC8JYs4vGf5Z9dBDjezZNSNmM0IgzVtecjtH3rAUcvAPs5zhIY31qIchhhW2P84hTAJk66NPa4LyWzkYwWU0QOjBWJsCyN7i1ixYvcgLg3vfFozeLD9ufRexW3dD6Tq4DwRkIboUHmWyOjEdoby5dhONtP0Rv93ez28fi-eXh6fbmudBlTVLRUKpqpQ1omBqmOeelUpRXcg6K6KmalEry3GllKtANZzCZglJEaaorpnh5iE43uUPwn0uISXQ2anBO9uCXUWQUZcmqOhunG6MOPsYAczEE28mwEpSINXbxi12smQrOxC92QfPeyfbAUmUqf1tbzlm_3uiQv_yyEETUmYDOAAPoJIy3_1z4AffYlVQ</recordid><startdate>19981001</startdate><enddate>19981001</enddate><creator>Wylie, James P</creator><creator>Cowan, Richard A</creator><creator>Deakin, David P</creator><general>Elsevier Ireland Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19981001</creationdate><title>The role of radiotherapy in the treatment of localised intermediate and high grade non-Hodgkin's lymphoma in elderly patients</title><author>Wylie, James P ; Cowan, Richard A ; Deakin, David P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c360t-711b6bcdece5d8c9993bb194afeb0c5b23ba9c5b14d4ec798e25ebb0bc1c48b93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Age Factors</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Disease-Free Survival</topic><topic>Elderly</topic><topic>Female</topic><topic>High/intermediate grade</topic><topic>Humans</topic><topic>Lymphoma, Non-Hodgkin - mortality</topic><topic>Lymphoma, Non-Hodgkin - radiotherapy</topic><topic>Male</topic><topic>Non-Hodgkin's lymphoma</topic><topic>Radiotherapy</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wylie, James P</creatorcontrib><creatorcontrib>Cowan, Richard A</creatorcontrib><creatorcontrib>Deakin, David P</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Radiotherapy and oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wylie, James P</au><au>Cowan, Richard A</au><au>Deakin, David P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The role of radiotherapy in the treatment of localised intermediate and high grade non-Hodgkin's lymphoma in elderly patients</atitle><jtitle>Radiotherapy and oncology</jtitle><addtitle>Radiother Oncol</addtitle><date>1998-10-01</date><risdate>1998</risdate><volume>49</volume><issue>1</issue><spage>9</spage><epage>14</epage><pages>9-14</pages><issn>0167-8140</issn><eissn>1879-0887</eissn><abstract>Background and purpose: The treatment of elderly patients with high or intermediate grade non-Hodgkin's lymphoma (NHL) remains difficult and controversial. In order to audit our own practice, 270 elderly patients treated between 1988 and 1993 with this diagnosis were retrospectively reviewed. Material and methods: 81 patients unfit for chemotherapy received fractionated radiotherapy for apparently localised stage I or II disease. The median age of the patients was 78 years (range 70–87 years). Forty stage I and 17 stage II patients had extra-nodal sites of disease. The radiation field included the primary site plus immediate adjacent nodes. Results: After a median follow-up of 3.9 years the 5-year overall and disease-free survival rates were 33% and 31%, respectively. Age (hazard ratio (HR) 1.22, P=0.03), stage (HR 5.50, P=0.02) and lactate dehydrogenase level (HR 1.003, P=0.004) were identified as independent risk factors for relapse. Conclusion: These factors can define a group in which radiotherapy can produce acceptable survival rates (age≤80 years, stage I and lactate dehydrogenase≤500). This group represented 34% of those patients where all these variables were recorded and had 5-year disease-free and overall survival rates of 56% and 62%, respectively.</abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>9886691</pmid><doi>10.1016/S0167-8140(98)00068-1</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0167-8140
ispartof Radiotherapy and oncology, 1998-10, Vol.49 (1), p.9-14
issn 0167-8140
1879-0887
language eng
recordid cdi_proquest_miscellaneous_69133846
source MEDLINE; Elsevier ScienceDirect Journals
subjects Age Factors
Aged
Aged, 80 and over
Disease-Free Survival
Elderly
Female
High/intermediate grade
Humans
Lymphoma, Non-Hodgkin - mortality
Lymphoma, Non-Hodgkin - radiotherapy
Male
Non-Hodgkin's lymphoma
Radiotherapy
Survival Rate
title The role of radiotherapy in the treatment of localised intermediate and high grade non-Hodgkin's lymphoma in elderly patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T07%3A59%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20role%20of%20radiotherapy%20in%20the%20treatment%20of%20localised%20intermediate%20and%20high%20grade%20non-Hodgkin's%20lymphoma%20in%20elderly%20patients&rft.jtitle=Radiotherapy%20and%20oncology&rft.au=Wylie,%20James%20P&rft.date=1998-10-01&rft.volume=49&rft.issue=1&rft.spage=9&rft.epage=14&rft.pages=9-14&rft.issn=0167-8140&rft.eissn=1879-0887&rft_id=info:doi/10.1016/S0167-8140(98)00068-1&rft_dat=%3Cproquest_cross%3E69133846%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69133846&rft_id=info:pmid/9886691&rft_els_id=S0167814098000681&rfr_iscdi=true